Innate Pharma (NASDAQ:IPHA) Upgraded to Hold at Zacks Investment Research

Innate Pharma (NASDAQ:IPHA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The […]

Related Keywords

United States ,France ,America , ,Sigma Securities ,Zacks Investment Research ,Balyasny Asset Management ,Affinity Asset Advisors ,America Corp ,Innate Pharma Company Profile Get Rating ,Pura Vida Investments ,Innate Pharma ,Get Rating ,Asset Management ,Vida Investments ,Asset Advisors ,Pharma Company Profile ,Nasdaq Ipha ,Wipha ,Medical ,Upgrade ,